Eli Lilly and Co. (NYSE:LLY) – Jefferies Group issued their Q3 2016 EPS estimates for Eli Lilly and in a research report issued on Thursday. Jefferies Group analyst J. Holford anticipates that the firm will earn $0.98 per share for the quarter. Jefferies Group has a “Buy” rating and a $105.00 price target on the stock. Jefferies Group also issued estimates for Eli Lilly and’s FY2019 earnings at $5.61 EPS.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 26th. The company reported $0.86 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.86. Eli Lilly and had a return on equity of 23.99% and a net margin of 11.97%. The firm had revenue of $5.40 billion for the quarter, compared to analyst estimates of $5.14 billion. During the same quarter last year, the company earned $0.90 EPS. The company’s revenue was up 8.6% on a year-over-year basis.
LLY has been the topic of a number of other research reports. Deutsche Bank AG restated a “buy” rating on shares of Eli Lilly and in a research note on Tuesday, September 20th. Leerink Swann reiterated a “buy” rating and issued a $103.00 price objective on shares of Eli Lilly and in a research note on Sunday, October 9th. Credit Suisse Group AG reiterated a “buy” rating and issued a $91.00 price objective on shares of Eli Lilly and in a research note on Wednesday, July 6th. Zacks Investment Research downgraded Eli Lilly and from a “buy” rating to a “hold” rating in a research note on Wednesday, October 5th. Finally, Goldman Sachs Group Inc. upgraded Eli Lilly and from a “neutral” rating to a “buy” rating and upped their price objective for the company from $89.00 to $95.00 in a research note on Tuesday, September 27th. Three analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Eli Lilly and currently has a consensus rating of “Buy” and a consensus price target of $97.06.
Eli Lilly and (NYSE:LLY) opened at 79.27 on Friday. The firm’s 50-day moving average price is $79.73 and its 200-day moving average price is $77.79. Eli Lilly and has a 1-year low of $67.88 and a 1-year high of $88.16. The company has a market cap of $83.84 billion, a price-to-earnings ratio of 34.17 and a beta of 0.17.
Several hedge funds have recently bought and sold shares of LLY. Iowa State Bank purchased a new stake in Eli Lilly and during the second quarter worth $104,000. PineBridge Investments L.P. raised its stake in Eli Lilly and by 208.6% in the second quarter. PineBridge Investments L.P. now owns 1,361 shares of the company’s stock worth $108,000 after buying an additional 920 shares in the last quarter. Cribstone Capital Management LLC purchased a new stake in Eli Lilly and during the second quarter worth $117,000. Coconut Grove Bank raised its stake in Eli Lilly and by 3.3% in the second quarter. Coconut Grove Bank now owns 1,550 shares of the company’s stock worth $122,000 after buying an additional 50 shares in the last quarter. Finally, Physicians Financial Services Inc. raised its stake in Eli Lilly and by 11.2% in the second quarter. Physicians Financial Services Inc. now owns 1,638 shares of the company’s stock worth $129,000 after buying an additional 165 shares in the last quarter. Institutional investors own 74.96% of the company’s stock.
In other news, major shareholder Lilly Endowment Inc sold 240,000 shares of the stock in a transaction dated Thursday, July 28th. The shares were sold at an average price of $82.87, for a total transaction of $19,888,800.00. Following the completion of the sale, the insider now directly owns 126,020,570 shares in the company, valued at $10,443,324,635.90. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Maria A. Crowe sold 2,248 shares of the stock in a transaction dated Wednesday, October 5th. The stock was sold at an average price of $81.37, for a total transaction of $182,919.76. Following the sale, the insider now owns 94,319 shares of the company’s stock, valued at $7,674,737.03. The disclosure for this sale can be found here. Company insiders own 0.20% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related companies with MarketBeat.com's FREE daily email newsletter.